A detailed history of Jennison Associates LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 15,291 shares of HALO stock, worth $852,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,291
Holding current value
$852,779
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 24, 2025

BUY
$42.57 - $61.09 $650,937 - $934,127
15,291 New
15,291 $731,000
Q1 2023

Apr 26, 2023

BUY
$32.86 - $55.7 $562,924 - $954,196
17,131 New
17,131 $654,000
Q2 2022

Aug 02, 2022

SELL
$37.35 - $48.3 $1.11 Million - $1.43 Million
-29,658 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$31.97 - $41.06 $948,166 - $1.22 Million
29,658 New
29,658 $1.18 Million
Q1 2020

May 06, 2020

SELL
$13.9 - $21.83 $369,628 - $580,503
-26,592 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$14.93 - $19.53 $397,018 - $519,341
26,592 New
26,592 $471,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.77B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.